Olema Pharmaceuticals

OLMA

Market cap $2.57B

SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 12:55 p.m. ET. Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema's investor relations website at ir.olema.com.

Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell shares of its common stock, or for certain investors that so choose, in lieu of shares of common stock, pre-funded warrants to purchase shares of its common stock. All of the securities are being offered by Olema.

Drugmakers are making notable deals, biotech is coming back, and much of the worry about tariffs and interest rates has faded away.

Shares of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) soared Tuesday in reaction to Roche Holdings AG‘s (OTC: RHHBY) phase 3 results from the lidERA Breast Cancer study of giredestrant in early-stage breast cancer.

Olema Pharmaceuticals' (NASDAQ: OLMA stock) soared 197% in pre-market trading on Tuesday morning, despite no company announcements from Olema itself. The dramatic spike sent shockwaves through the biotech sector and caught traders off guard.

Olema Pharmaceuticals Inc. (NASDAQ: OLMA) stock is trading higher on Tuesday, with a session volume of 45.12 million compared to the average volume of 1.171 million as per data from Benzinga Pro.

Biotech stock Olema Pharmaceuticals catapulted to a four-year high Tuesday after Roche unveiled positive results in breast cancer treatment.

Announced new clinical trial agreement with Pfizer to evaluate palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancer Initiated OPERA-02 Phase 3 trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer Presented compelling new data from Phase 1b/2 study of palazestrant plus ribociclib at ESMO 2025 Ended the quarter with $329.0 million in cash, cash equivalents, and marketable securities SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the third quarter ended September 30, 2025. "We have made significant progress advancing our programs this quarter, highlighted by the initiation of the Phase 3 OPERA-02 trial evaluating palazestrant in combination with ribociclib in the frontline setting and the presentation of compelling data at ESMO that further positions palazestrant to become a potential best-in-class backbone endocrine therapy for ER+/HER2- metastatic breast cancer,” said Sean P.

SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to five new employees to purchase an aggregate of 148,600 shares of the Company's common stock, effective as of November 3, 2025. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).